The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Their study, published recently in Nature, focuses on what is known as the estrogen receptor, a protein linked in previous research to the development of roughly 70% of all breast tumors.

A significant aspect of breast cancer management is the assessment of estrogen receptor (ER) status, as it plays a vital role in determining treatment options. Recent advancements in imaging ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

What they are losing is estrogen, which affects the brain wiring responsible for memory and how fast you process information.

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

In the first years following a diagnosis, survival rates are lower, compared to hormone receptor-positive cancers, but, unlike hormonal receptor-positive tumors—which are notorious for having late ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...